Opioid vaccine study for adults with heroin or fentanyl use
Part of Mental health clinical trials.
This trial tests a vaccine made from parts designed to help the body respond to opioids (heroin or fentanyl). It is mainly for adults with moderate-to-severe opioid use disorder who are using opioids that match the study dosing needs and who are willing to do frequent visits over about a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be able to sign informed consent and follow study rules
- Be age 18 to 59
- If you are female: not pregnant or breastfeeding, and use medically acceptable birth control (or not able to become pregnant)
- Use heroin and/or fentanyl by intranasal route (at least 1–2 bags/day, up to 20 bags/day) and prefer an opioid other than common prescription ones like oxycodone
- Not be in medication treatment for opioid use disorder (no methadone, buprenorphine, or naltrexone) and have urine tests that do not show illicit opioids or current opioid-treatment medicines right before enrollment
- Be medically able to take the vaccine (no serious allergies to opioid/alum vaccine ingredients, no major liver/kidney/heart/lung issues, and meet basic blood count limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
This study tests two different forms of buprenorphine (a medication for opioid addiction) to see which works better for people who use fentanyl or other strong synthetic opioids. If you are seeking treatment for opioid use, this trial may help you find the most effective option.
This early-stage study tests a new approach for opioid use disorder in adults. It aims to understand safety and how the treatment may work in people with opioid addiction.
This trial tests whether starting buprenorphine using a low-dose plan is a safe and workable way to treat opioid use disorder. You may be able to join if you are 18+, have opioid use disorder, and can follow the study medication and visits.
This Phase 3 study tests whether starting a high dose of buprenorphine in the emergency department helps people with opioid use disorder come through withdrawal more safely and effectively. It focuses on people whose urine test shows fentanyl and who are already in withdrawal when they arrive.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.